Intrinsic Alpha

Company Snapshot

X4 Pharmaceuticals, Inc. investment report

Start with XFOR at a glance, then work through valuation, price history, fundamentals, management, competitors, and analyst expectations.

X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Biotechnology

Healthcare
$2.96 +1.49%

+$0.06 today

Market cap
$302.26M
Beta
0.37
P/E (TTM)
-5.2
EPS (TTM)
-$0.79
52W Low $1.35High $4.83

Volume 1.12M

Average 0.40M

Intrinsic Value

XFOR Intrinsic Value

Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.

X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Intrinsic Alpha fair value

Locked

Current Price

$2.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.

Monitor XFOR

Get notified when the price moves into your range

Use alerts to turn the valuation into an action plan instead of checking the stock manually.

Price alerts

Get notified when XFOR drops below your target

Current price baseline

$2.96

Current price

Current price $2.96

Selected target$2.37

Sign in to activate price alerts.

Price History

How has XFOR traded over time?

Review how the market has priced X4 Pharmaceuticals, Inc. over time, alongside earnings and dividend events, before deciding whether today’s price is unusual.

Price history

Dividend-adjusted closing price

Period change

-20.00%

Period high

$4.67

Period low

$2.45

Latest

$2.96

Investment Notes

Capture the investment case

Write down the key idea, risks, and what would change your mind before testing the thesis against the fundamentals below.

My notes

Journal entries for XFOR

Sign in to keep notes

Keep your research and decisions in your personal journal.

Sign in / Sign up

Fundamental Analysis

Test company quality against your thesis

Work through profitability, revenue mix, financial position, cash generation, compounding numbers, and growth to see whether the business supports the investment case.

Earnings Quality

Follow revenue through to net income

Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.

XFOR Earnings Waterfall · TTM

NASDAQ:XFOR · Revenue to Net Income

Key Ratios

EPS$-4.54
Gross Margin79.2%
Net Margin-1168.3%
P/E Ratio-3.1
P/S Ratio113.9

Analysis

$9.0M of revenue converted into -$99.7M of net income for the selected period. Gross margin is 79.2% and net margin is -1168.3%, showing how much revenue survives after costs and taxes. EPS is $-4.54, tying the income statement back to per-share earnings.

Revenue Mix

See which products and regions drive the business

Growth is easier to trust when you know where it comes from. Check whether one segment or region carries the company and how the mix is shifting.

Revenue by segment

Where XFOR earns its revenue, as reported in company filings

  • License and Other Revenue
  • Product
  • Product Returns
Revenue by segment for FY2025
Segment · FY2025 Revenue Share YoY
License and Other Revenue$28.59M81.4%—
Product$6.52M18.6%—

Figures in USD.

Financial Position

Check what supports the company underneath the income statement

The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$216.9M
Short-term Investments$16.8M
Receivables$1.1M
Inventory$4.6M
Other Current$2.5M
Total Current Assets$242.0M
PP&E (Net)$1.2M
Goodwill$17.4M
Intangible Assets$9.1M
Other Non-current$704.0K
Total Non-current Assets$28.3M
Total Assets$270.3M

Analysis

Selected assets total $270.3M for Latest. The largest visible component is Cash & Equivalents at $216.9M, about 80.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Cash Generation

Test whether profit turns into cash

Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$79.2M
+ D&A$1.3M
+ Stock-Based Comp$4.3M
+ Deferred Tax$0
- Working Capital-$2.6M
- Other Non-Cash-$9.4M
= Operating Cash Flow-$85.6M
- Capex-$3.0M
= Free Cash Flow-$88.6M

Analysis

FY2025 free cash flow is -$88.6M. FCF conversion is 111.9% of net income. Operating cash flow was -$85.6M, with capex of -$3.0M. The largest bridge item is Other Non-Cash at -$9.4M.

Quality Snapshot

Check the numbers that compound value

Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
Not availableNot availableNot availableNot available
Revenue
Not availableNot availableNot available+1,273.2%
Equity
Not availableNot available-49.9%+33.3%
Cash
Not availableNot available+21.3%+289.7%
ROIC
Not available-57.3%-50.0%-32.7%

Analysis

In the latest year, Revenue was strongest at +1,273.2%, while ROIC was weakest at -32.7%. The three-year average ROIC was -50.0%, a measure of how efficiently the company earned that growth.

Growth Profile

Compare historical growth with forward expectations

Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+71.7% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Forward estimates point to Revenue at +71.7% (5yr), giving you a quick read on expected growth from here.

Management

Judge how X4 Pharmaceuticals, Inc. allocates capital

Review returns on capital, owner payouts, dividend durability, insider activity, and the leadership responsible for these decisions.

Capital Efficiency

Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-42.5%

avg -12.1%

ROIC

-32.7%

avg -460.5%

ROA

-27.3%

avg -105.3%

Analysis

ROA is currently the strongest return metric at -27.3% versus its period average of -105.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Dividend Record

A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.

Dividends

Dividend history, growth & yield

Dividends

Yield

0.00%

Annual Div/Share

$0.00

Payout Ratio

0.0%

Frequency

—

Shareholder Yield

0.00%

Next Ex-Date

Not announced

Next Payment

—

Analysis

The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.

Owner Returns

Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.

Shareholder Returns

Dividend, buyback & debt paydown yields

Management

Dividend Yield (TTM)

0.00%

Buyback Yield (TTM)

0.00%

Debt Paydown (TTM)

0.00%

Total Yield (TTM)

0.00%

Showing limited history. Sign in for more

Analysis

Total TTM shareholder yield is 0.00% including 0.00% from debt paydown. The largest current contributor is dividends at 0.00%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.

Insider Activity

Insider transactions add context to ownership incentives and can reveal when leadership behavior diverges from the public investment case.

Insider Trading

SEC Form 4 transactions — last 12 months

Management

Buys

1

$11,883.64

Sells

5

$462,964.22

Net Transaction Value

−$451,080.58

Net selling

Most Active

KIRSKE DAVID

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 16, 26

Craig Adam R

Direct

Buy$11.9K
Oct 1, 26

KIRSKE DAVID

Direct

Sell$33.7K
Aug 12, 26

Volpone John

Direct

Sell$109.2K
Aug 12, 26

Craig Adam R

Direct

Sell$210.8K
Jun 30, 26

KIRSKE DAVID

Direct

Sell$36.4K
May 12, 26

KIRSKE DAVID

Direct

Sell$72.8K

Summary

Insiders reported 1 buys worth $11,883.64 and 5 sells worth $462,964.22 over the last 12 months. That adds up to net selling of $451,080.58. KIRSKE DAVID was the most active insider with 3 transactions.

Leadership

Leadership context helps you judge who is responsible for strategy, capital allocation, and execution.

Management

Key executives, compensation & ownership

View management
NameTitleCompensationAgeShares OwnedOwnership %

David H. Kirske

Chief Financial Officer, Treasurer & Corporate SecretaryUSD 722.33K72——

Adam R. Craig

Executive ChairUSD 575.55K60333.25K0.35%

John Volpone

President & Chief Operating OfficerUSD 532.99K51265.31K0.28%

Keith T. Flaherty

Founder & Member of Corporate Advisory Board—55——

Richard Peters

Founder—64——

Renato T. Skerlj

Founder————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 16, 2026.

Alternatives to XFOR

Compare X4 Pharmaceuticals, Inc. with similar companies

A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.

Analysts

What Wall Street expects from XFOR

Compare consensus price targets and ratings with your own valuation to understand how much optimism the market is already pricing in.

Analyst Targets

See where analysts expect XFOR to trade next

Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for XFOR.

Sign in free

Analyst Ratings

How analysts rate XFOR today

See the buy, hold, and sell split behind the consensus and whether recent rating changes lean toward upgrades or downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for XFOR.

Sign in free

Company Overview

Understand how X4 Pharmaceuticals, Inc. makes money

Ground the financial evidence in the company profile, business description, and key facts.

Key Information

Filings
NameX4 Pharmaceuticals, Inc.
TickerXFOR
ExchangeNASDAQ Capital Market
IPO DateNov 16, 2017
IndustryBiotechnology
SectorHealthcare
Market Cap$302.26M
Shares Out94.32M
LocationBoston, MA, US

Stock Analysis

Turn the XFOR report into your next decision

Record your conclusion, evidence, and concerns in a structured analysis workspace.

Investment analysis

Turn XFOR research into a decision

Work through Know the Business, Test the Moat, Management, and Intrinsic Value in one private, repeatable checklist.

NASDAQ:XFOR
Know the Business
Test the Moat
Management
Intrinsic Value

Sign in on the next page to save a private analysis.

Start analysis

FAQ

Common questions about XFOR

Resolve the remaining questions before moving into the detailed workspaces.

Explore

Continue your research

Open the detailed valuation, financial, health, and management workspaces.